ADC Therapeutics SA (ADCT) is a Healthcare · Biotechnology company listed on NYSE. Price $1.05 (-0.94%), Market cap $0.41B, 52-week low–high $1.89 ~ $4.88.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal
Financial statements, price targets, institutional (13F) holdings and related news for ADC Therapeutics SA are updated in real time on BlackAll Trade.
ADC Therapeutics SA trades at $1.05 (-0.94%). Real-time quotes and charts are available on BlackAll Trade.
ADC Therapeutics SA has a market cap of about $0.41B.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated a